Rohto stock holds steady as investors eye record FY2025 figures

Published on 09/02/2026 at 12:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rohto stock is supported by solid recent fundamentals, with investors focusing on the company’s record FY2025 performance and segment growth while watching the latest price levels on the Tokyo Stock Exchange.

Rohto, JP3982400008, Illustration mit AI erstellt.

Rohto stock (ISIN JP3982400008) is drawing investor attention as the Japanese healthcare group’s most recent integrated report shows record revenue for fiscal year 2025, giving the market a concrete basis for valuation as of September 2, 2026.

Record revenue and profit in FY2025

According to Rohto Pharmaceutical’s 2025 integrated report, the company’s fiscal year 2025 ran from April 1, 2024 to March 31, 2025, and marked a new revenue high for the group.

In that period, Rohto reported consolidated net sales of 270.8 billion JPY, which the company highlighted as a record level compared with previous years, underlining the growth trajectory in its core skincare and eye care segments.

This FY2025 revenue represented an increase versus historical levels stated in earlier reports, with the integrated report emphasizing that net sales had moved above the 250 billion JPY mark, underlining a clear expansion of the business base.

Operational scale and segment momentum

The same set of integrated disclosures indicates that Rohto operated with 7,259 consolidated employees as of March 31, 2024, illustrating the scale of its global healthcare franchise ahead of the FY2025 record revenue period.

Management commentary in the integrated report points to continued growth in skincare and eye care products, which helped lift consolidated net sales to 270.8 billion JPY in FY2025 and supported profitability at group level.

For investors, the key point is that Rohto has managed to expand its top line while maintaining a broad international footprint, with thousands of employees and multiple brands contributing to the revenue stream.

Go deeper

More background on Rohto and its stock

Investors can find additional details on Rohto’s earnings history and market performance as well as broader news about the stock and its sector peers.

All Rohto stock news on ad-hoc-news.de Investor Relations

Representative consumer product: Rohto eye drops

One of Rohto’s best-known products in many markets is its branded eye drops, which form a core part of the company’s ophthalmic portfolio and contribute meaningfully to its consolidated net sales.

These eye care products are sold broadly through retail and e-commerce channels and help underpin the company’s positioning in over-the-counter healthcare, complementing its skincare and other consumer health offerings.

Rohto stock and investor focus

Rohto shares are listed on the Tokyo Stock Exchange, giving investors exposure to the company’s record FY2025 revenue of 270.8 billion JPY and its sizeable workforce of more than 7,000 employees as of the end of the most recent reporting periods.

For shareholders, the combination of sustained revenue growth and a broad product portfolio in eye care and skincare remains central to the investment case for Rohto stock as of September 2, 2026.